You are on page 1of 8

Available online at http://www.urpjournals.

com

International Journal of Pharmaceutical and Clinical Science


Universal Research Publications. All rights reserved

Original Article

A Review- Formulation of Mouth Dissolving tablet


P. Ashish 1*, M.S. Harsoliya2, J.K.Pathan1, S. Shruti1
1. Swami Vivekanand College of Pharmacy, Indore
2. Research Scholar, JJT University, Rajasthan

Received 31 May 2011; accepted 16 June 2011

Abstract

Mouth dissolving tablets are solid dosage forms containing drugs that disintegrate in the oral cavity within less than one minute
leaving an easy-to-swallow residue. In the recent trend the development of mouth dissolving tablets formulation is emerging
and gaining popularity because it is easy to administer and leads to better patient compliance. These dosage forms are placed in
the mouth, allowed to disperse or dissolve in the saliva. The release the drug as soon as they come in contact with the saliva,
thus obviating the need for water during administration. The aim of this article is to review the progress of the evolving
technologies and super disintegrating agents in the formulation, manufacturing and evaluation of these tablets.This article also
discusses the new evaluation methodologies for these orally disintegrating tablets. Various modifications in the conventional
evaluation and use of specialized instruments are found to be essential in the testing of these dosage forms. In the present
review the formulation techniques and different technologies are discussed.
© 2011 Universal Research Publications. All rights reserved
Key words: Mouth dissolving tablet, Conventional techniques, Rapid Disintegration

Introduction European Pharmacopeia adopted the term orodispersible


In recent decades, a variety of pharmaceutical research has tablet for a tablet that disperses or disintegrates in less than 3
been conducted to develop new dosage forms. Considering minutes in the mouth before swallowing. Such a tablet
quality of life, most of these efforts have been focused on disintegrates into smaller granules or melts in the mouth from
ease of medication. Among the various dosage forms a hard solid to a gel-like structure, allowing easy swallowing
developed to improve the ease of administration, the mouth by patients. The disintegration time for good MDTs varies
dissolving tablet (MDT) is the most widely preferred from several seconds to about a minute 2,3,4. Orally
commercial products 1. The oral cavity is an attractive site for disintegrating tablets provide an advantage particularly for
the administration of drugs because of ease of administration. pediatric and geriatric populations who have difficulty in
Various dosage forms like Tablets, Capsules, Liquid swallowing conventional tablets and capsules. Additionally,
preparations are administered by oral route 7. During the pediatric patients may suffer from ingestion problems as a
last decade, mouth dissolving tablet (MDT) technologies that result of underdeveloped muscular and nervous control.
make tablets disintegrate in the mouth without chewing and Moreover, patients traveling with little or no access to water,
additional water intake have drawn a great deal of attention. limit utility of orally administered conventional tablets or
The MDT is also known as fast melting, fast dispersing, rapid capsules. Mouth dissolving of tablet results in quick
dissolve, rapid melt, and or quick disintegrating tablet. All dissolution and rapid absorption which provide rapid onset of
MDTs approved by the Food and Drug Administration (FDA) action. Moreover, drug candidates that undergo pre-gastric
are classified as orally disintegrating tablets. Recently, the absorption when formulated as MDTs may show increased
International Journal of Pharmaceutical and Clinical Science 2011; 1 (1): 1-8
1
oral bioavailability. It provides good stability, accurate  Pre-gastric absorption can result in improved
dosing, easy manufacturing 5,6. bioavailability and as a result of reduced dosage,
improved clinical performance through a reduction of
Ideal Properties7,8 : unwanted effects.
An ideal MDT should:
 Require no water for oral administration. Disadvantage8:
 Have a pleasing mouth feel.
 Have an acceptable taste masking property.  Fast dissolving tablet is hygroscopic in nature so must
 Be harder and less friable. be keep in dry place.
 Leave minimal or no residue in mouth after  Some time it possesses mouth feeling.
administration.  MDT requires special packaging for properly
 Exhibit low sensitivity to environmental conditions stabilization & safety of stable product.
(temperature and humidity). Technology for Mouth dissolving Tablets:
 Allow the manufacture of tablet using
conventional processing and packaging equipments.
Conventional Techniques 7:
Advantages7,8:
 Administration to the patients who cannot swallow, Disintegrates addition:
such as the elderly, bedridden patients, patients
affected by renal failure & patients who refuse to Disintegrate addition technique is one popular techniques for
swallow such as pediatric, geriatric & psychiatric formulating Fast-dissolving tablets because of its easy
patients. implementation and cost-effectiveness. The basic principle
 Rapid drug therapy intervention. involved in formulating Fast-dissolving tablets by
 Achieve increased bioavailability/rapid absorption disintegrates addition technique is addition of
through pre-gastric absorption of drugs from mouth, superdisintegrants in optimum concentration so as to achieve
pharynx & esophagus as saliva passes down. mouth dissolving along with the good mouth feel.
 Convenient for administration and patient compliant
for disabled, bedridden patients and for travelers and Molding:
busy people, who do not always have access to water.
 Good mouth feel property helps to change the In this method, molded tablets are prepared by using water-
perception of medication as bitter pill particularly in soluble ingredients so that the tablets dissolve completely and
pediatric patients. rapidly. The powder blend is moistened with a hydro-
 The risk of chocking or suffocation during oral alcoholic solvent and is molded into tablets under pressure
administration of conventional formulations due to lower than that used in conventional tablet compression. The
physical obstruction is avoided, thus providing solvent is then removed by air-drying. Molded tablets are
improved safety. very less compact than compressed tablets. These possess
 New business opportunity like product differentiation. porous structure that enhances dissolution.

Salient Features7: Freeze drying:


 Ease of administration to patients who refuse to
swallow a tablet, such as pediatric and geriatric A process in which water is sublimated from the product after
patients and, psychiatric patients. freezing. Lyophilization is a pharmaceutical technology
 Convenience of administration and accurate dosing as which allows drying of heat sensitive drugs and biological at
compared to liquids. low temperature under conditions that allow removal of water
 Rapid dissolution of drug and absorption which may by sublimation. Lyophilization results in preparations, which
produce rapid, onset of action. are highly porous, with a very high specific surface area,
 Some drugs are absorbed from the pharynx and which dissolve rapidly and show improved absorption and
oesophagus as the saliva passes down into the bioavailability.
stomach, in such cases bioavailability of drugs is
increased. Sublimation:
 Ability to provide advantages of liquid medication in The slow dissolution of the compressed tablet containing
the form of solid preparation. even highly water-soluble ingredients is due to the low
porosity of the tablets. Inert solid ingredients that volatilize
International Journal of Pharmaceutical and Clinical Science 2011; 1 (1): 1-8
2
Marketed Products3:

Table 1: Marketed product of MDTs


Brand name Active ingredient Application company
Claritin® RediTabs® Loratadine Antihistamine Scherig corporation
Feldene Melt® Piroxicam NSAIDs Pfizer
Maxalt® -MLT® Rizatritpan benzoate Migrane Merck
®
Pepeid ODT Femotidene Anti-ulcer Merck
®
Zyperxa Olazepine Psychotropic Eli Lilly
Zofran® ODT Olandansetron Antiemetic Galaxo Smith kline
Resperdal® M-TabTM Resperidone Schizophrenia Janssen
TM
Zubrin (Pet drug) Tepoxelin Canine NSAIDs Scherig corporation
ZelaparTM Selegiline Parkinsons disease Elanl Amarin corporation

Klonopin® wafer Clonazepam Sedation Roche


®
Childrens Dimetapp ND Loratadine Allergy Wyeth consumer
Healthcare
Imodium Istant Melts Loperamide HCL Antidiarrheal Jannsen
Propulsid® Cisapride Monohydrate Gastrointestinal Jannsen
Quicksolv ® prokinetic Agent

Tempra Quicksolv® Acetaminophen Analgesic Bristol-Mters squibb


Remeron® Soltab® Mirtazapine Anti-dipression Organon Inc.
® ®
Triaminic Softchews Various combination Pediatric cold Novartis consumer Health
cough,Allergy
Zomig-ZMT® and Zolmitriptan Anti-migraine AstraZeneca Alavert®
Rapimelt® AstraZeneca Loratadine Allergy

DuraSolv® Alavert® Loratadine Allergy Wyeth Consumer


Healthcare
NuLev® Hyoscyamine sulfate Anti-ulcer Schwarz Pharma
Kemstro™ Baclofen Anti-spastic Schwarz Pharma
analgesic
Benadryl® Fastmelt® Diphenhydramine sinus pressure relief Pfizer
citrate

Nasea OD Ramosetoron HCl Anti-emetic Yamanouchi


Gaster D Famotidine Anti-ulcer Yamanouchi
Excedrin® QuickTabs Acetaminophen Pain reliever Bristol-Myers Squibb

readily (e.g. urea, ammonium carbonate, ammonium removed via sublimation, which generates porous structures.
bicarbonate, hexa methelene tetramine, camphor etc.) were Additionally, several solvents (e.g. cyclohexane, benzene)
added to the other tablet ingredients and the mixture is can be also used as pore forming agents.
compressed into tablets. The volatile materials were then
International Journal of Pharmaceutical and Clinical Science 2011; 1 (1): 1-8
3
Table No.2: Relationship between % compressibility and flow ability
% Compressibility Flow ability
5 – 12 Excellent
12 – 16 Good
18 – 21 Fair Passable
23 – 35 Poor
33 – 38 Very Poor
< 40 Very Very Poor

Table No.3: Angle of Repose as an Indication of Powder Flow Properties


Sr. No Angle of Repose (°) Type of Flow

1 < 20 Excellent
2 20 – 30 Good
3 30 – 34 Passable
4 > 34 Very Poor

Table No.3: Weight Variation Specification as per IP


Average Weight of Tablet % Deviation

80 mg or less ±10
More than 80 mg but less than 250 mg ±7.5
250 mg or more ±5

Spray-Drying: accommodated and final weight of tablet can easily exceed


Spray drying can produce highly porous and fine powders that of other production methods. Directly compressed
that dissolve rapidly. The formulations are incorporated by tablet's disintegration and solubilization depends on single or
hydrolyzed and non hydrolyzed gelatins as supporting agents, combined action of disintegrants, water soluble excipients
mannitol as bulking agent, sodium starch glycolate or cross and effervescent agent.
carmellose sodium as disintegrating and an acidic material
(e.g. citric acid) and or alkali material (e.g. I sodium Patented Technology3,7:
bicarbonate) to enhance disintegration and dissolution. Tablet Flashtab Technology:
compressed from the spray dried powder disintegrated within Prographarm laboratories have patented the Flashtab
20 seconds when immersed in an aqueous medium. technology. Tablets prepared by this system consist of an
active ingredient in the form of micro crystals. Drug micro
Mass-Extrusion: granules may be prepared by using the conventional
This technology involves softening the active blend using the techniques like coacervation, micro encapsulation, and
solvent mixture of water soluble polyethylene glycol, using extrusion spheronisation. All the processing utilized
methanol and expulsion of softened mass through the conventional tabletting technology.
extruder or syringe to get a cylinder of the product into even
segments using heated blade to form tablets. The dried Wowtab Technology:
cylinder can also be used to coat granules of bitter tasting Wowtab Technology is patented by "Yamanouchi
drugs and thereby masking their bitter taste. Pharmaceutical Co. " WOW means "Without Water ". In this
process, combination of low mouldability saccharides and
Direct compration: high mouldability saccharides is used to obtain a rapidly
Direct compration method is the easiest way to manufacture melting strong tablet. The active ingredient is mixed with a
tablets. Conventional equipment, commonly available low mouldability saccharide and granulated with a high
excipients and a limited number of processing steps are mouldability saccharide and compressed into tablet.
involved in direct compression. Also high doses can be

International Journal of Pharmaceutical and Clinical Science 2011; 1 (1): 1-8


4
Flash Dose Technology: cylinder can also be used to coat granules of bitter tasting
Flash dose technology has been patented by "Fuisz". Nurofen drugs and thereby masking their bitter taste.
meltlet, a new form of ibuprofen as melt-in-mouth tablets,
prepared using flash dose technology is the first commercial Criteria for Drug Selection9:
product launched by" Biovail Corporation". Flash dose  The ideal characteristics of a drug for in vivo
tablets consists of self binding shearform matrix termed as dissolution from an MDT include:-
"floss". Shearform matrices are prepared by flash heat  No bitter taste.
processing.  Dose lower than 20mg.
 Small to moderate molecular weight.
Orasolv Technology:  Good stability in water and saliva.
Orasolv Technology has been developed by "CIMA" labs. In  Partially non-ionized at the oral cavities pH.
this system active medicament is taste masked. It also  Ability to diffuse and partition into the epithelium of
contains effervescent disintegrating agent. Tablets are made the upper GIT.
by direct compression technique at low compression force in  Ability to permeate oral mucosal tissue.
order to minimize oral dissolution time. Conventional
blenders and tablet machine is used to produce the tablets.
 Unsuitable drug characteristic for MDT:-
The tablets produced are soft and friable and packaged in
 Short half-life and frequent dosing.
specially designed pick and place system.
 Very bitter or otherwise unacceptable taste because
taste masking cannot be achieved.
Durasolv Technology:
Durasolv is the patented technology of "CIMA" labs. The  Required controlled or sustained release.
tablets made by this technology consist of a drug, fillers and a
lubricant. Tablets are prepared by using conventional Super Disintegrants Used in MDTs8,10:
tableting equipment and have good rigidity. These can be As day’s passes, demand for faster disintegrating
packed into conventional packaging system like blisters. formulation is increased. So, pharmacist needs to formulate
Durasolv is an appropriate technology for products requiring disintegrants i.e. Superdisintegrants which are effective at
low amounts of active ingredients. low concentration and have greater disintegrating efficiency
and they are more effective intragranularly.
Zydis Technology: This superdisintegrants act by swelling and due to swelling
This technology involves softening the active blend using the pressure exerted in the outer direction or radial direction, it
solvent mixture of water soluble polyethylene glycol, using causes tablet to burst or the accelerated absorption of water
methanol and expulsion of softened mass through the leading to an enormous increase in the volume of granules to
extruder or syringe to get a cylinder of the product into even promote disintegration.
segments using heated blade to form tablets. The dried

Fig.1: Mechanism of superdisintegrants by swelling Fig.2: Mechanism of tablet disintegration

International Journal of Pharmaceutical and Clinical Science 2011; 1 (1): 1-8


5
Varioustypes of Super disintegrants used are as follows – The value below 15% indicates a powder with give rice to
 Crosspovidone good flow properties, whereas above 25% indicate poor
 Microcrystalline cellulose flowability. Which is calculated follows.
 Sodium starch glycollate
 Sodium carboxy methyl cellulose or cross carmelose % C.I. = ρt - ρb ρt ˟ 100
sodium
 Pregelatinzed starch Hausner ratio12:
 Calcium carboxy methyl cellulose Hausner ratio is an indirect index of ease of powder flow.
 Modified corn starch. Sodium starch glycollate has Hosner ratio is the ratio of tapped density to bulk density.
good flowability than crosscarmellose sodium. Lower the value of Housner ratio better is the flow property.
Powder with Housner ratio less than 1.18, 1.19, 1.25, 1.3- 1.5
Factors to be considered for selection of superdisintegrants: and greater the 1.5 indicate excellent, good, passable, and
very poor, respectively. It is calculated by following formula.
 It should produce mouth dissolving when tablet
meets saliva in the mouth Hausner ratio = ρt ρt
 It should be compactable enough to produce less-
friable tablets. Porosity11,14:
 It can able to produce good mouth feel to the patient. Percent relative porosity (ε) was obtained using the
Thus, small particle size is preferred to achieve relationship between apparent density (ρapp) and true density
patient compliance. (ρtrue) which is calculated by following formula.
 It should has good flow since it improve the ε = ( 1 - ρapp / ρtrue) ˣ 100
flowability of the total blend.
Voide Volume11:
Preformulation Studies Voide volume(V) was obtained by difference between bulk
Bulk Density11,12: volume(Vb) and tapped volume (Vp).Voide volume can be
Apparent bulk density was determine by pouring the 5 gram
calculated by following formula.
of powder V = Vb - Vp into a 100 ml
granulated cylinder. The
bulk volume (V) poured drug was determined. The bulk
density was calculated using the formula.
Angle of repose12,14:
The angle of repose was determined using funnel method.
ρb = M / V Funnel that can be fit vertically with stand at 6.3 cm. height.
The opening end of funnel are closed with thumb until drug
Were : ɋ b - bulk density,M- is the weight of powder, V- is the are poured. The 5 gm of powder was poured into funnel that
volume of powder. can be raised vertically until a maximum cone hight (h) was
ϴ = Tan-1 ( h / r ) obtained. Radius of the heap (r) was measured and the angle
of repose (ϴ) was calculated using the formula.
Tapped Density11,12:
Weight 5 g. of powder and placed in a measuring cylinder.
Measuring cylinder containing known mass (5 gm) of powder Evaluation of Mouth dissolving Tablets By-
was tapped for 100 times or fixed time. The minimum Thickness15:
volume (Vt) occupied was measured. The tapped density was Tablet thickness can be measured using a simple procedure. 5
calculated using following formula. tablets were taken and their thickness was measured using
Varnier calipers.
ρt = M / Vt
Hardness13,16:
Compressibility Index : 12,13 It is the force required to break a tablet by compression in the
The simplest way for measurement of free flow of powder is radial direction, it is an important parameter in formulation of
compressibility, a indication of the ease with which a material mouth dissolve tablets because excessive crushing strength
can be induced to flow is given by Compressibility Index. significantly reduces the disintegration time.In the present

International Journal of Pharmaceutical and Clinical Science 2011; 1 (1): 1-8


6
study the crushing strength of the tablet was measured us-ing In-vitro dispersion time test15:
Pfizer hardness testers. An average of three observations is To determine dispersion time 10 ml measuring cylinder was
reported. taken in which 6 ml distilled water was added and tablet was
Uniformity of weight17,13: dropped in it. Time required for complete dispersion was
I.P. procedure for uniformity of weight was followed, twenty determined.
tablets were taken and their weight was determined Wetting time 15,17:
individually and collectively on a digital weighing balance. Five circular tissue papers of 10 cm diameter are placed in a
The average weight of one tablet was determined from the petridish with a 10 cm diameter. Ten millimeters of water-
collective weight. The weight variation test would be a containing Eosin, a water-soluble dye, is added to petridish.
satisfactory method of determining the drug content A tablet is carefully placed on the surface of the tissue paper.
uniformity. The time required for water to reach upper surface of the
Disintegration time17 tablet is noted as a wetting time.
The test was carried out on 6 tablets using the apparatus
specified in I.P.-1996 distilled water at 37ºC ± 2ºC was used Water absorption ratio17:
as a disintegration media and the time in second taken for A piece of tissue paper folded twice was placed in a small
complete disintegration of the tablet with no palatable mass Petri dish containing 6 ml of water. A tablet was put on the
remaining in the apparatus was measured in seconds. paper & the time required for complete wetting was
measured. The wetted tablet was then weighed. Water
In-vitro drug release17: absorption ratio (R), was determined using following
The development of dissolution methods for ODTs is equation,
comparable to the approach taken for conventional tablets,
and is practically identical. Dissolution conditions for drugs R = 10 ( Wa /Wb)
listed in a pharmacopoeia monograph, is a good place to start Where- Wb is weight of tablet before water absorption & Wa
with scouting runs for a bioequivalent ODT. Other media is weight of tablet after water absorption.
such as 0.1N HCl and buffers (pH - 4.5 and 6.8) should be Accelerated Stability study17:
evaluated for ODT much in the same way as their ordinary The Orally disintegrating tablets are packed in suitable
tablet counter parts. packaging and stored under the following conditions for a
The USP 2 Paddle apparatus is used for this purpose which is period as prescribed by ICH guidelines for accelerated
the most suitable and common choice for orally- studies.
disintegrating tablets, with a paddle speed of 50 rpm (i) 40 ± 1 °C
commonly used. Typically the dissolution of ODT is very fast (ii) 50 ± 1°c
when using USP monograph conditions; hence slower paddle (iii) 37 ±1 ° C and Relative Humidity= 75% ± 5%
speeds may be utilized to obtain a profile. The USP 1 Basket The tablets were withdrawn after a period of 15 days and
apparatus may have certain applications but sometimes tablet analyzed for physical characterization (Visual defects,
fragments or disintegrated tablet masses may become trapped Hardness, Friability, Disintegrations, and Dissolution etc.)
on the inside top of the basket at the spindle where little or no and drug content. The data obtained is fitted into first order
effective stirring occurs, yielding irreproducible dissolution equations to determine the kinetics of degradation.
profiles. Accelerated stability data are plotting according Arrhenius
equation to determine the shelf life at 25 ° C.
Friability test18,13:
Friability of the tablets was determined using Roche friability Packaging8
(Electrolab, Mumbai). This device subjects the tablets to the Packaging special care is required during manufacturing and
combined effect of abrasions and shock in a plastic chamber storage to protect the dosage of other fast-dissolving dosage
revolving at 25 rpm and dropping the tablets at a height of 6 forms. Quick-dispersing and/or dissolving oral delivery
inches in each revolution. Preweighed sample of tablets was systems, the system can be packaged using various options,
placed in the friabilator and were subjected to 100 such as single pouch, blister card with multiple units,
revolutions. Tablets were de dusted using a soft muslin cloth multipleunit dispenser, and continuous roll dispenser,
and reweighed. The friability (f) is given by the formula. depending on the application and marketing objectives.

f = (1- W0 / W) × 100
Conclusion:
Where, W0 is weight of the tablets before the test and W is Mouth dissolving Tablets is the general form of nomenclature
the weight of the tablet after the test. for tablets that disintegrate rapidly or instantly in the oral
cavity. MDTs have better patient acceptance and compliance
International Journal of Pharmaceutical and Clinical Science 2011; 1 (1): 1-8
7
and may offer improved biopharmaceutical properties, promethazine theoclate Mouth dissolving tablets; The
improved efficacy, and better safety compared with Indian pharmacist., 65- 68.
conventional oral dosage forms. MDTs can be prepared in 5. Prajapati G.B., Patel S.B., (2010)., Formulation,
different ways and product performance depends upon the Evaluation and Optimization of Orally Disintegrating
drug suitability and excipients selections in the delivery Tablet of Piroxicam; International Journal of PharmTech
system. In combination with other technologies such as Research., 1893-1899.
modified release and microencapsulation, MDTs will 6. Mohan A. and Ghosh S.K., (2010)., Fast Dissolving
continue to provide enhanced commercial and therapeutic Tablets: Past, Present and Future; Indian drug 47(6).,5-
benefits. MDT is a growing technology, offering considerable 11.
benefits for lifecycle management16, development timelines, 7. Sharma S., (2008)., New generation of tablet: Fast
patient convenience and market share. By paying close dissolving tablet; Latest review Vol VI .
attention to advances in technologies, pharmaceutical 8. Kumari S., Visht S., Sharma P.K., Yadav R.K., (2010).,
companies can take advantage of MDTs for product line ex- Fast dissolving Drug delivery system : Review Article;
tensions or for first-to-market products. With continued Journal of Pharmacy Research 3(6).,1444-1449.
development of new pharmaceutical excipients, one can 9. C. Kumaresan., (2008)., Orally Disintegrating Tablet -
expect the emergence of more novel technologies for MDTs Mouth dissolving, Sweet Taste, And Target Release
in the days to come. The successful marketed MDTs have Profile; Pharmaceutical review Vol-6.
good taste and rapid release properties. With rapid acceptance 10. Solanki A.B., Parikh J.R., Parikh R.H., (2007).,
of MDTs by patients and pharmaceutical companies, the Formulation and Optimization of Piroxicam Proniosomes
market for this dosage form is promising, and the product by 3-Factor, 3-Level Box-Behnken Design; AAPS
pipeline continues to grow rapidly. PharmSciTech. 8(4).
11. Sinko. J. Patrick Martins., Physical pharmacy and
Acknowledgement(s): Pharmaceutical science, 5th edition distributed by B.I.
Mr. Sohel Harsoliya would like to acknowledge the support Publication PVT Ltd., 232.
during this review from Research Scholar, JJT university, 12. Patel S.S., Pate M.S., Patel N.M., (2009)., Flowability
Rajasthan & J.K.Pathan for its esteemed support and testing of directly compressible excipients accordind to
encouragement. british pharmacopoeia; Journal of Pharmaceutical
Research Vol. 8. 66 -69.
References: 13. D. Bhowmik et al., ( 2009)., Fast Dissolving Tablet: An
1. S. J.R., Nayak S., Amlan S., Deep V.V., Khemariya P., Overview; Journal of Chemical and Pharmaceutical
Sumbhate S., Nayak S.,(2009)., Taste masking of Research.,163-177.
Lornoxicam by polymer carrier system and formulation 14. O.M. Javier, Hong M., M.G. Aubey, T.M. Jason.,
of oral disintegrating tablets; International Journal of (2010)., Orally Disintegrating Tablets using starch and
Drug Delivery., 27-31. fructose; Pharmaceutical Technology.,92-99.
2. Fu Yourong , Yang S., Jeong S. H., Kimura S., & Park 15. Shaikh S et al., (2010)., Formulation and evaluation of
K., (2004)., Therapeutic Drug Carrier Systems, Orally orodispersible tablets of piroxicam.,IJPI’s Journal of
Fast Disintegrating Tablets:Developments, Pharmaceutics and Cosmetology., 2-8.
Technologies,Taste-Masking and Clinical 16. Panigrahi R., Behera S.,( 2010)., A Review On Fast
Studies;Critical Reviews™ 21(6).,433–475. Dissolving Tablets., WebmedCentral Quality and patient
3. Chaudhari P.D., Chaudhari S.P., Lanke S.D. and Patel safety WMC00809., 1-15.
N.,( 2007)., Formulation and in vitro evaluation of teste 17. Mahaveer Pr. Khinchi., (2010)., Orally disintegrating
masked orodispersible dosage form of Levocetirizine tablets: A future prospectus., Int J Pharm Sci Bio., 71-79.
dihydrochloride; Indian journal of pharmacuitical 18. Modasiya M.K. et al., (2009)., Design and
Education and research 41(4).,319-327. Characterization of Fast Disintegrating Tablets of
4. Nayak U.K., Patra S.K., Rout P.K., Patro B.K. and Piroxicam., International Journal of PharmTech
Nayak B.S., (2008)., Development and optimization of Research., 353-357.

Source of support: Nil; Conflict of interest: None declared

International Journal of Pharmaceutical and Clinical Science 2011; 1 (1): 1-8


8

You might also like